# Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

> **NCT00463788** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 181 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** cetuximab, cisplatin
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00463788
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-07
- **Final completion:** 2011-02
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2014-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463788, "Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00463788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*